XCXueman Chen

Xueman Chen

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Xueman Chen has a total of 31 co-authors. Here are the top co-authors by number of shared publications:

  • Di Huang

    Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation Guangdong‐Hong Kong Joint Laboratory for RNA Medicine Breast Tumor Center Sun Yat‐sen Memorial Hospital Sun Yat‐sen University Guangzhou 510120 China

    2 shared publications
  • Erwei Song

    Breast Tumor Center, Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Medical Research Center, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, People’s Republic of China

    2 shared publications
  • Yan Nie

    Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Breast Tumor Center, Sun Yat-sen Memorial Hospital, Sun Yat-sen University

    2 shared publications
  • Yunmei Zhang

    Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Medical Research Center, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University

    2 shared publications
  • Ailifeire Yilihamu

    Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Guangdong-Hong Kong Joint Laboratory for RNA Medicine, Medical Research Center, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou 510120, China

    1 shared publication
  • Duoguang Wu

    Department of Thoracic Surgery, Sun Yat‐sen Memorial Hospital Sun Yat‐sen University Guangzhou China

    1 shared publication

Latest Publications

  • Open Access

    Multicenter Retrospective Study of the Impact of Localized Therapy on Prognosis in Patients With Oligometastatic Solid Tumors

    by Xueman Deng, Duoguang Wu, Luting Ni, Wei Li, Zhijun Liu, Jiewei Liu, Jieqiong Liu

    Background: Local therapy has recently been applied to treat oligometastatic cancer across various malignant cancers. However, definitive evidence for local treatment regimens remains lacking. We aimed to evaluate the clinical outcomes of combining local therapy with systemic treatment for patients with oligometastatic solid tumors including breast cancer, liver cancer, and non‐small cell lung cancer (NSCLC) in a multicenter retrospective study. Methods: From January 2013 to December 2023, 575 patients with fewer than or equal to five metastases of breast cancer, liver cancer, and NSCLC in three tertiary university hospitals were analyzed retrospectively. The primary endpoint was overall survival (OS). The secondary endpoints included progression‐free survival (PFS) and prognostic factors affecting the treatment outcomes. Results: Before propensity score matching, significant differences were observed in both OS and PFS between the local therapy plus systemic therapy and systemic therapy alone groups ( p < 0.001 and p < 0.001). After PSM, PFS remained significantly different ( p = 0.017), but OS did not ( p = 0.076). In liver cancer, before PSM analysis showed a significant PFS benefit ( p = 0.011), which was absent after PSM for both OS and PFS ( p = 0.568 and p = 0.363). For both breast cancer and NSCLC patients, no significant differences in OS or PFS were found after PSM. Conclusions: Local treatment of solitary metastatic lesions showed that no statistically significant difference was observed in OS or PFS of patients with advanced oligometastatic breast, liver cancer, and NSCLC.

  • Top Cited Papers
    Open Access

    Immunometabolic editing of the tumor microenvironment: from reprogramming mechanisms to therapeutic vulnerabilities

    by Yixin Li, Yunmei Zhang, Yan Nie, Xueman Chen

    Metabolic reprogramming is not only one of the malignant characteristics of tumor cells, but also commonly seen in a variety of immune cells in tumor microenvironment(TME), which massively promotes tumor-body immune interaction. Immunometabolic editing is a dynamic, co-evolutionary process wherein adaptive metabolic reprogramming in the TME, driven by tumor-immune crosstalk during immunoediting, critically shapes anti-tumor immune response and governs immune evasion. Studies of metabolic pathways linked to anti-tumor immune process and discoveries of important therapeutic targets are conducive to the development of targeted immunometabolic intervention to enhance the body’s anti-tumor immune response and improve the efficacy of tumor immunotherapies. This review summarizes metabolic characteristics of the TME, highlights immunometabolic editing during cancer evolution, and discusses mechanisms by which tumor immunotherapies modulate tumor immunometabolism to identify potential therapeutic targets.


  • Open Access

    LncRNA ZFPM2-AS1 promotes phyllodes tumor progression by binding to CDC42 and inhibiting STAT1 activation

    by Shishi He, Guowei Huang, Rong Lei, Rurong Jia, Zhanghai He, Jiewen Chen, Hongyan Huang, Zixian Huang, Ailifeire Yilihamu, Xun Li, et al.


  • Open Access

    Long noncoding RNA DIO3OS induces glycolytic-dominant metabolic reprogramming to promote aromatase inhibitor resistance in breast cancer

    by Xueman Chen, Rong Luo, Yunmei Zhang, Shuying Ye, Xin Zeng, Jiang Liu, Di Huang, Yujie Liu, Qiang Liu, Man-Li Luo, et al.

    Aromatase inhibition is an efficient endocrine therapy to block ectopic estrogen production for postmenopausal estrogen receptor (ER)-positive breast cancer patients, but many develop resistance. Here, we show that aromatase inhibitor (AI)-resistant breast tumors display features of enhanced aerobic glycolysis with upregulation of long noncoding RNA (lncRNA) DIO3OS, which correlates with poor prognosis of breast cancer patients on AI therapies. Long-term estrogen deprivation induces DIO3OS expression in ER-positive breast tumor cells, which further enhances aerobic glycolysis and promotes estrogen-independent cell proliferation in vitro and in vivo. Mechanistically, DIO3OS interacts with polypyrimidine tract binding protein 1 (PTBP1) and stabilizes the mRNA of lactate dehydrogenase A (LDHA) by protecting the integrity of its 3’UTR, and subsequently upregulates LDHA expression and activates glycolytic metabolism in AI-resistant breast cancer cells. Our findings highlight the role of lncRNA in regulating the key enzyme of glycolytic metabolism in response to endocrine therapies and the potential of targeting DIO3OS to reverse AI resistance in ER-positive breast cancer.


  • The Dawning of Translational Breast Cancer: From Bench to Bedside

    by Xueman Chen, Siting Fan, Erwei Song

    Breast cancer is one of the world’s leading causes of death in women. Although tumor initiation and progression are predominantly driven by somatic or acquired (epi) genetic alterations that govern signaling abnormalities, growing evidence suggests that the inflammatory microenvironments of cancer also play a role. Molecular characterization of breast cancer biology is essential for high-efficient management of this disease in clinical practice. Translating basic research into clinically valuable biomarkers for diagnosis, prognosis, and prediction of response to treatment and into precisely targeted therapies is crucial for the development of precision medicine in breast cancer. Such a process is known as “from bench to bedside.” In this chapter, we will present an overview of breast cancer pathogenesis and selected translational advances in multistage clinical settings and aim to illustrate the dawning of precision medicine implementation in managing human breast malignancies.